Pamela L. Kunz, MD

Dr Kunz on Time to Response With Lutetium Lu 177 Dotatate in GEP-NETs

June 13th 2024

Pamela L. Kunz, MD, discusses a subanalysis of the NETTER-2 study investigating frontline lutetium Lu 177 dotatate in advanced, well-differentiated GEP-NETs.

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

NETs Management: Unmet Needs and Future Direction

June 19th 2020

NETs Data Updates at ASCO 2020

June 19th 2020

NETTER-1 Clinical Trial Overview

June 19th 2020

Subcutaneous Pen Formulation FDA Approval

June 19th 2020

Inoperable NETs: The Role of Systemic Therapy

June 19th 2020

New Biomarkers for Diagnosis and Prognosis

June 19th 2020

Optimal Sequencing Strategy for NETs

June 19th 2020

NETs Treatment Landscape and Selection Factors

June 19th 2020

Dr. Kunz on the CLARINET Study for GEP-NETs

January 26th 2016

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses tumor response in the CLARINET study, which examined lanreotide depot versus placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Dr. Kunz on Potential of Immunotherapy in Neuroendocrine Tumors

October 17th 2015

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Dr. Kunz on Anticipated Trial Results for Patients with Neuroendocrine and Carcinoid Tumors

March 4th 2015

Pamela L. Kunz, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses some anticipated trial results for patients with neuroendocrine and carcinoid tumors.

Dr. Kunz on Sequencing Agents for Pancreatic NETs

October 10th 2014

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.

Dr. Kunz on Identifying Gastric Cancer Subtypes

April 23rd 2014

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses the effort to identify molecular subtypes of gastric cancer.

Dr. Kunz on Treatment Options for Pancreatic NETs

February 10th 2014

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses current and future treatment options for patients with neuroendocrine tumors (NETs).